Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.45 Analyst target: $7.00 Upside: 382.76%
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California.
See the full interactive analysis & chart →Informational only — not investment advice.